DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Use of Clonidine to Prevent Withdrawal Following Prolonged Dexmedetomidine Infusions

Information source: Nationwide Children's Hospital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Sedation

Intervention: Clonidine (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: Joseph D. Tobias

Official(s) and/or principal investigator(s):
Joseph D Tobias, MD, Principal Investigator, Affiliation: Nationwide Children's Hospital

Overall contact:
Julie Rice, RN, Phone: 6143553142, Email: julie.rice@nationwidechildrens.org


The investigators' clinical practice makes use of oral clonidine as a means of transitioning from intravenous dexmedetomidine following prolonged infusions (more than 3-5 days). Although this is common clinical practice, there is limited clinical data to demonstrate the efficacy of this technique and to provide clonidine dosing guidelines. The purpose of this study is to retrospectively review the investigators' experience with the use of oral clonidine to prevent withdrawal following the prolonged administration of dexmedetomidine.

Clinical Details

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome: Evidence of withdrawal


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients who received clonidine during the transition from dexmedetomidine.

Exclusion Criteria:

- None

Locations and Contacts

Julie Rice, RN, Phone: 6143553142, Email: julie.rice@nationwidechildrens.org

Additional Information

Starting date: April 2015
Last updated: March 30, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017